Akebia Therapeutics Company Profile (NASDAQ:AKBA)

About Akebia Therapeutics (NASDAQ:AKBA)

Akebia Therapeutics logoAkebia Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics based on hypoxia-inducible factor (HIF) biology. The Company's lead product candidate, vadadustat, is indicated for the treatment of anemia in chronic kidney disease (CKD). It is involved in developing vadadustat as an oral therapy. The Company's vadadustat is a HIF-prolyl-hydroxylase (HIF-PH) inhibitor in Phase III development for the treatment of anemia of CKD. In addition to vadadustat, the Company is engaged in developing a HIF-based portfolio of product candidates that target serious diseases of unmet need. Its portfolio includes product candidates developed internally, such as AKB-6899, as well as in-licensed product candidates, including AKB-5169. AKB-5169 is a preclinical compound in development as an oral treatment for inflammatory bowel disease (IBD).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:AKBA
  • CUSIP: N/A
  • Web: www.akebia.com
Capitalization:
  • Market Cap: $253.46 million
  • Outstanding Shares: 18,300,000
Average Prices:
  • 50 Day Moving Avg: $11.68
  • 200 Day Moving Avg: $9.96
  • 52 Week Range: $7.00 - $15.88
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -5.58
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $22.4 million
  • Price / Sales: 11.31
  • Book Value: $0.79 per share
  • Price / Book: 17.53
Profitability:
  • EBIDTA: ($154,490,000.00)
  • Return on Equity: -88.40%
  • Return on Assets: -64.59%
Debt:
  • Current Ratio: 6.32%
  • Quick Ratio: 6.32%
Misc:
  • Average Volume: 885,973 shs.
  • Beta: 1.07
  • Short Ratio: 5.66
 

Frequently Asked Questions for Akebia Therapeutics (NASDAQ:AKBA)

What is Akebia Therapeutics' stock symbol?

Akebia Therapeutics trades on the NASDAQ under the ticker symbol "AKBA."

How were Akebia Therapeutics' earnings last quarter?

Akebia Therapeutics Inc (NASDAQ:AKBA) issued its quarterly earnings data on Tuesday, May, 9th. The company reported ($1.15) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.15) by $1.00. The company earned $20.87 million during the quarter, compared to analyst estimates of $16.50 million. View Akebia Therapeutics' Earnings History.

Where is Akebia Therapeutics' stock going? Where will Akebia Therapeutics' stock price be in 2017?

6 brokers have issued twelve-month target prices for Akebia Therapeutics' shares. Their forecasts range from $8.00 to $25.00. On average, they expect Akebia Therapeutics' share price to reach $19.67 in the next twelve months. View Analyst Ratings for Akebia Therapeutics.

What are analysts saying about Akebia Therapeutics stock?

Here are some recent quotes from research analysts about Akebia Therapeutics stock:

  • 1. Aegis analysts commented, "Well known brands in the ESA market place include Epogen and Aranesp by Amgen, Procrit and Eprex by J&J, and Mirceraby Roche. Emerging, direct competitors in the HIF-PH class include Akebia’s vadadustat, Fibrogen’s roxadustat, Bayer’s molidustat, and Glaxo Smithkline’s daprodustat. Among the HIP-PH product candidates in development, Fibrogen (FGEN, non-rated) is positioned to obtain regulatory approval first, potentially as early 2019, followed by Akebia’s vadadustat in 2020. In our opinion, Akebia’s potential 18 month lag behind Fibrogen (FGEN, non-rated) could work well for the company as we anticipate a gradual adoption of the HIF-PH class by nephrologists. According to surveys conducted by Decision Resource Group in 2015, most nephrologists – over 60% of those surveyed – do not yet differentiate between the oral HIF-PH inhibitors in development." (3/24/2017)
  • 2. According to Zacks Investment Research, "Akebia Therapeutics Inc. is a biopharmaceutical company. It focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor biology for patients with kidney disease. Akebia Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. " (2/28/2017)
  • 3. Brean Capital analysts commented, "We like Akebia's asset, vadadustat, which is a new MOA for treating anemia. If successfully developed, it could change the standard of care," analyst Difei Yang wrote in a note.Related Link: Sarepta Dosing First Patients In Phase 3 Trial Of Duchenne Muscular Dystrophy Drug"International partnerships aside, Akebia will commercialize vadadustat on its own in the US and we project sales to be around $515 mil in 2022, with sales for ND-CKD indication alone," (9/29/2016)

Who are some of Akebia Therapeutics' key competitors?

Who owns Akebia Therapeutics stock?

Akebia Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Eagle Asset Management Inc. (19.40%), First Manhattan Co. (9.32%), Vanguard Group Inc. (7.11%), FMR LLC (5.09%), Morgan Stanley (4.76%) and MARSHALL WACE ASIA Ltd (3.78%). Company insiders that own Akebia Therapeutics stock include Duane Nash, Michel Dahan and Nicole R Hadas. View Institutional Ownership Trends for Akebia Therapeutics.

Who sold Akebia Therapeutics stock? Who is selling Akebia Therapeutics stock?

Akebia Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Marshall Wace LLP, Perceptive Advisors LLC, City Financial Investment Co Ltd, Bank of America Corp DE, JPMorgan Chase & Co., Trexquant Investment LP, Segantii Capital Management Ltd and Highbridge Capital Management LLC. Company insiders that have sold Akebia Therapeutics stock in the last year include Duane Nash and Nicole R Hadas. View Insider Buying and Selling for Akebia Therapeutics.

Who bought Akebia Therapeutics stock? Who is buying Akebia Therapeutics stock?

Akebia Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including MARSHALL WACE ASIA Ltd, Marshall Wace North America L.P., First Manhattan Co., Acadian Asset Management LLC, Renaissance Technologies LLC, Vanguard Group Inc., TFS Capital LLC and Russell Investments Group Ltd.. View Insider Buying and Selling for Akebia Therapeutics.

How do I buy Akebia Therapeutics stock?

Shares of Akebia Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Akebia Therapeutics stock cost?

One share of Akebia Therapeutics stock can currently be purchased for approximately $13.85.

Analyst Ratings

Consensus Ratings for Akebia Therapeutics (NASDAQ:AKBA) (?)
Ratings Breakdown: 2 Hold Ratings, 4 Buy Ratings
Consensus Rating:Buy (Score: 2.67)
Consensus Price Target: $19.67 (42.00% upside)

Analysts' Ratings History for Akebia Therapeutics (NASDAQ:AKBA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017AegisReiterated RatingBuy$25.00LowView Rating Details
5/17/2017Needham & Company LLCReiterated RatingBuy$18.00 -> $21.00LowView Rating Details
5/17/2017HC WainwrightReiterated RatingNeutral$21.00 -> $25.00LowView Rating Details
4/26/2017JMP SecuritiesBoost Price TargetOutperform$19.00 -> $21.00HighView Rating Details
9/29/2016Brean CapitalInitiated CoverageBuy$18.00N/AView Rating Details
8/9/2016Credit Suisse Group AGReiterated RatingHold$8.00N/AView Rating Details
5/8/2016Morgan StanleyReiterated RatingBuyN/AView Rating Details
3/9/2016JPMorgan Chase & Co.Lower Price TargetMarket Outperform$24.00 -> $16.00N/AView Rating Details
(Data available from 5/25/2015 forward)

Earnings

Earnings History for Akebia Therapeutics (NASDAQ:AKBA)
Earnings by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Earnings History by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/9/2017Q1 2017($0.15)($1.15)$16.50 million$20.87 millionViewN/AView Earnings Details
3/6/2017Q4 2016$0.77($0.99)$125.00 million$1.54 millionViewListenView Earnings Details
11/9/2016Q3($1.09)($0.96)ViewN/AView Earnings Details
8/8/2016Q2 2016($0.57)($0.95)$6.00 millionViewN/AView Earnings Details
5/5/2016Q1 2016($0.43)($0.70)$9.00 millionViewN/AView Earnings Details
3/14/2016Q415($0.28)($0.66)$11.60 millionViewListenView Earnings Details
11/9/2015Q3($0.52)($0.68)ViewN/AView Earnings Details
8/11/2015Q215($0.51)($0.40)ViewN/AView Earnings Details
5/11/2015Q1 2015($0.57)($0.53)ViewN/AView Earnings Details
3/4/2015Q414($0.66)($0.52)ViewN/AView Earnings Details
11/10/2014Q314($0.45)($0.47)ViewN/AView Earnings Details
8/11/2014Q2 2014($0.34)($0.39)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Akebia Therapeutics (NASDAQ:AKBA)
Current Year EPS Consensus Estimate: $-3.46 EPS
Next Year EPS Consensus Estimate: $-2.48 EPS

Dividends

Dividend History for Akebia Therapeutics (NASDAQ:AKBA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Akebia Therapeutics (NASDAQ:AKBA)
Insider Ownership Percentage: 7.95%
Institutional Ownership Percentage: 49.50%
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Institutional Ownership by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Insider Trades by Quarter for Akebia Therapeutics (NASDAQ:AKBA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
4/3/2017Duane NashDirectorSell991$9.20$9,117.20View SEC Filing  
4/3/2017Nicole R HadasSVPSell1,556$9.18$14,284.08View SEC Filing  
1/3/2017Duane NashDirectorSell1,980$10.46$20,710.80View SEC Filing  
1/1/2017Nicole R. HadasSVPSell1,810$10.49$18,986.90View SEC Filing  
7/6/2016Duane NashDirectorSell1,980$7.48$14,810.40View SEC Filing  
7/5/2016Nicole R. HadasSVPSell1,557$7.47$11,630.79View SEC Filing  
4/4/2016Michel DahanSVPSell1,401$9.41$13,183.41View SEC Filing  
10/2/2015Nicole R HadasSVPSell1,484$8.67$12,866.28View SEC Filing  
7/2/2015Nicole R HadasSVPSell1,484$9.54$14,157.36View SEC Filing  
4/22/2015Muneer A SatterDirectorBuy420,000$8.25$3,465,000.00View SEC Filing  
4/2/2015Nicole R HadasSVPSell1,483$9.09$13,480.47View SEC Filing  
1/2/2015Nicole R HadasVPSell1,715$11.46$19,653.90View SEC Filing  
12/29/2014John P ButlerCEOBuy1,000$11.57$11,570.00View SEC Filing  
12/26/2014Duane NashDirectorSell11,933$11.23$134,007.59View SEC Filing  
12/22/2014John P ButlerCEOBuy1,000$11.92$11,920.00View SEC Filing  
12/15/2014John P ButlerCEOBuy1,000$11.34$11,340.00View SEC Filing  
12/2/2014Ronald C Renaud JrDirectorBuy5,000$11.92$59,600.00View SEC Filing  
11/26/2014Jason AmelloCFOBuy1,000$13.22$13,220.00View SEC Filing  
11/25/2014Muneer A SatterDirectorBuy5,000$13.18$65,900.00View SEC Filing  
11/24/2014Muneer A SatterDirectorBuy5,000$13.88$69,400.00View SEC Filing  
11/21/2014Muneer A SatterDirectorBuy5,000$14.73$73,650.00View SEC Filing  
11/20/2014Muneer A SatterDirectorBuy5,000$14.70$73,500.00View SEC Filing  
11/19/2014Muneer A SatterDirectorBuy5,000$14.85$74,250.00View SEC Filing  
11/18/2014Muneer A SatterDirectorBuy5,000$13.84$69,200.00View SEC Filing  
11/17/2014Muneer A SatterDirectorBuy5,000$12.94$64,700.00View SEC Filing  
11/14/2014Muneer A SatterDirectorBuy5,000$11.91$59,550.00View SEC Filing  
11/13/2014Muneer A SatterDirectorBuy5,000$11.56$57,800.00View SEC Filing  
11/12/2014John P ButlerCEOBuy1,000$10.31$10,310.00View SEC Filing  
11/12/2014Muneer A SatterDirectorBuy5,000$11.90$59,500.00View SEC Filing  
3/25/2014A/S NovoInsiderBuy182,590$17.00$3,104,030.00View SEC Filing  
3/25/2014Jason AmelloCFOBuy4,000$17.00$68,000.00View SEC Filing  
3/25/2014John P ButlerCEOBuy13,850$17.00$235,450.00View SEC Filing  
3/25/2014Muneer A SatterDirectorBuy91,295$17.00$1,552,015.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Akebia Therapeutics (NASDAQ:AKBA)
Latest Headlines for Akebia Therapeutics (NASDAQ:AKBA)
Source:
DateHeadline
streetinsider.com logoAkebia Therapeutics (AKBA) Appoints Rita Jain MD as Chief Medical Officer - StreetInsider.com
www.streetinsider.com - May 25 at 3:51 PM
finance.yahoo.com logoAkebia Therapeutics Names Rita Jain, M.D. as Chief Medical Officer
finance.yahoo.com - May 25 at 3:51 PM
streetinsider.com logoAkebia Therapeutics (AKBA) Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients - StreetInsider.com
www.streetinsider.com - May 24 at 3:25 PM
seekingalpha.com logoAkebia Therapeutics Breaking Out? - Seeking Alpha
seekingalpha.com - May 24 at 7:07 AM
finance.yahoo.com logoAkebia Initiates Phase 2 FO2RWARD Study of Vadadustat in Dialysis Patients with Anemia Related to Chronic Kidney Disease Hyporesponsive to Treatment with Erythropoiesis-Stimulating Agents
finance.yahoo.com - May 24 at 7:07 AM
investorplace.com logoAkebia Therapeutics Inc (AKBA) and Babcock & Wilcox Enterprises Inc (BW) Lead 18 Investor Reports - Investorplace.com
investorplace.com - May 23 at 3:27 PM
investorplace.com logoAkebia Therapeutics Inc (AKBA) and Babcock & Wilcox Enterprises Inc (BW) Lead 18 Investor Reports
investorplace.com - May 23 at 1:18 PM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - May 19 at 9:22 AM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Stock Rating Reaffirmed by Aegis
www.americanbankingnews.com - May 18 at 11:40 AM
americanbankingnews.com logoNeedham & Company LLC Reiterates "Buy" Rating for Akebia Therapeutics Inc (AKBA)
www.americanbankingnews.com - May 17 at 1:32 PM
finanznachrichten.de logoGainers & Losers Of May 16: AKBA, MTFB, TTNP, IMUC, CAPR...
www.finanznachrichten.de - May 17 at 12:31 PM
rttnews.com logoAkebia Therapeutics Inc. (AKBA) Broke Out To A New High On License Agreement
www.rttnews.com - May 17 at 12:31 PM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Earns Neutral Rating from HC Wainwright
www.americanbankingnews.com - May 17 at 11:00 AM
rttnews.com logoAkebia Therapeutics Inc. (AKBA) Is Climbing On License Agreement
www.rttnews.com - May 16 at 8:31 PM
nasdaq.com logoAkebia Therapeutics Inc. (AKBA) Has Jumped To A New High On License Agreement - Nasdaq
www.nasdaq.com - May 16 at 3:29 PM
nasdaq.com logoAKBA Abuzz, ANTH On Track For RESULT, IMUC Faces Cash Crunch, IONS Falls - Nasdaq
www.nasdaq.com - May 16 at 6:44 AM
streetinsider.com logoAkebia Therapeutics (AKBA), Vifor Pharma Enter Exclusive License Agreement to Provide Vadadustat to Fresenius ... - StreetInsider.com
www.streetinsider.com - May 16 at 6:44 AM
finance.yahoo.com logoAkebia and Vifor Pharma Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
finance.yahoo.com - May 16 at 6:44 AM
finance.yahoo.com logoVifor Pharma and Akebia Announce Exclusive License Agreement to Provide Vadadustat to Fresenius Medical Care in the U.S. Upon FDA Approval
finance.yahoo.com - May 16 at 6:44 AM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Announces Quarterly Earnings Results, Misses Expectations By $1.00 EPS
www.americanbankingnews.com - May 10 at 3:10 PM
finance.yahoo.com logoAkebia Announces First Quarter 2017 Financial Results
finance.yahoo.com - May 9 at 8:26 PM
finance.yahoo.com logoAkebia Therapeutics reports 1Q loss
finance.yahoo.com - May 9 at 8:26 PM
americanbankingnews.com logoAkebia Therapeutics (AKBA) Given Media Impact Score of -0.03
www.americanbankingnews.com - May 2 at 9:52 AM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) to Release Earnings on Wednesday
www.americanbankingnews.com - May 1 at 10:02 AM
americanbankingnews.com logoAkebia Therapeutics (AKBA) Given Daily Media Sentiment Score of 0.21
www.americanbankingnews.com - April 29 at 10:24 AM
finance.yahoo.com logoAkebia Therapeutics, Inc. – Value Analysis (NASDAQ:AKBA) : April 28, 2017
finance.yahoo.com - April 28 at 9:23 PM
finance.yahoo.com logoAkebia Therapeutics (AKBA) Shows Strength: Stock Up 5.8%
finance.yahoo.com - April 28 at 4:22 PM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Rating Reiterated by Aegis
www.americanbankingnews.com - April 28 at 10:52 AM
americanbankingnews.com logoNeedham & Company LLC Boosts Akebia Therapeutics Inc (AKBA) Price Target to $18.00
www.americanbankingnews.com - April 27 at 11:38 PM
rttnews.com logoAkebia Therapeutics Inc. (AKBA) Set A New High After Expanded License Agreement
www.rttnews.com - April 27 at 8:48 PM
benzinga.com logoUpside Of 124% Expected For Akebia Therapeutics Following Vadadustat Collaboration - Benzinga
www.benzinga.com - April 27 at 3:47 PM
streetinsider.com logoAkebia Therapeutics (AKBA) PT Raised to $18 at Needham & Company - StreetInsider.com
www.streetinsider.com - April 27 at 3:47 PM
finance.yahoo.com logoAkebia Therapeutics, Inc. breached its 50 day moving average in a Bullish Manner : AKBA-US : April 27, 2017
finance.yahoo.com - April 27 at 3:47 PM
finance.yahoo.com logo4 Things To Know About Akebia's New Vadadustat Collaboration With Otsuka Pharma
finance.yahoo.com - April 27 at 3:47 PM
americanbankingnews.com logoHC Wainwright Boosts Akebia Therapeutics Inc (AKBA) Price Target to $21.00
www.americanbankingnews.com - April 27 at 8:20 AM
finance.yahoo.com logoAkebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialize Vadadustat in Europe, China and Other Territories
finance.yahoo.com - April 27 at 1:40 AM
finance.yahoo.com logoAkebia and Otsuka Expand Relationship with Collaboration to Develop and Commercialise Vadadustat in Europe, China and Other Territories
finance.yahoo.com - April 27 at 1:40 AM
americanbankingnews.com logoAkebia Therapeutics' (AKBA) Outperform Rating Reaffirmed at JMP Securities
www.americanbankingnews.com - April 26 at 9:02 PM
nasdaq.com logoBUZZ-U.S. STOCKS ON THE MOVE-Twitter, Edwards Life, Akebia, Cree - Nasdaq
www.nasdaq.com - April 26 at 3:39 PM
finance.yahoo.com logoBiotech Movers: Akebia Soars on Expanded Partnership With Otsuka
finance.yahoo.com - April 26 at 3:39 PM
finance.yahoo.com logoAkebia Surges but is Still Undervalued, Making Takeover a Potential Remedy
finance.yahoo.com - April 26 at 3:39 PM
americanbankingnews.com logoAkebia Therapeutics (AKBA) Earning Favorable Media Coverage, Report Shows
www.americanbankingnews.com - April 26 at 2:16 PM
marketwatch.com logoAkebia shares jump on expanded anemia drug deal with Otsuka - MarketWatch
www.marketwatch.com - April 26 at 7:10 AM
streetinsider.com logoAkebia Therapeutics (AKBA), Otsuka Expand Vadadustat Pact - StreetInsider.com
www.streetinsider.com - April 26 at 7:10 AM
finance.yahoo.com logoAkebia shares jump on expanded anemia drug deal with Otsuka
finance.yahoo.com - April 26 at 7:10 AM
finance.yahoo.com logoAkebia expands anemia drug pact with Japanese firm, lifting shares
finance.yahoo.com - April 26 at 7:10 AM
americanbankingnews.com logoSomewhat Favorable Media Coverage Extremely Likely to Affect Akebia Therapeutics (AKBA) Share Price
www.americanbankingnews.com - April 23 at 7:50 AM
americanbankingnews.com logoSomewhat Favorable Press Coverage Extremely Likely to Affect Akebia Therapeutics (AKBA) Stock Price
www.americanbankingnews.com - April 20 at 12:41 PM
americanbankingnews.com logoAkebia Therapeutics (AKBA) Receives Media Sentiment Rating of -0.05
www.americanbankingnews.com - April 14 at 3:30 PM
americanbankingnews.com logoAkebia Therapeutics Inc (AKBA) Short Interest Update
www.americanbankingnews.com - April 8 at 12:50 PM

Social

Chart

Akebia Therapeutics (AKBA) Chart for Thursday, May, 25, 2017

This page was last updated on 5/25/2017 by MarketBeat.com Staff